Insight & Intelligence

More »

Feature Articles

More »

For full access to this article login to GEN Select now.

April 01, 2018 (Vol. 38, No. 7)

Supplement: HSP90 Inhibition Turns Up the Heat on Tumors

If “Cold” Tumors Become “Hot,” They Respond Better to Checkpoint Blockade Immunotherapy

  • The emergence and stunning early success of checkpoint blockade, a therapy that helps the immune system recognize and attack cancer cells, has garnered well-deserved headlines. Checkpoint blockade, however, benefits only a minority of cancer patients. While these patients harbor tumors that are responsive to checkpoint drugs such as anti-PD-1 ...

Not registered yet? Please fill out the form below and enjoy complimentary access to this and an exclusive collection of premium content and personalization features as a GEN Select insider. Learn More.

Get GEN Select Access Now

    • Do not put any letters or characters here if you are not a spy program.